Medication info
Januvia 100 mg (Sitagliptin Hydrochloride Monohydrate)

Januvia 100 mg (Sitagliptin Hydrochloride Monohydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.4mg / 1 tablet
Manufacturer / importer
Ilyang Pharmaceutical Co., Ltd.
Appearance
Light orange, round, double-convex film-coated tablet
Packaging
30 tablets (10 tablets/PTP X 3)
Approval status
Active

MFDS item code 202004066 · Approved 2020.05.29 · Insurance code 641706170

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This drug is administered once daily at a dose of 100 mg as monotherapy or in combination therapy, and the maximum daily dose is 100 mg. This drug may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see section 5. General Precautions, under Precautions for Use). Patients with renal impairment Since dosage adjustment is required according to renal function, evaluation of renal function is recommended before treatment with this drug and periodically thereafter. 1. No dosage adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. In patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. 4. In patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This drug may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Ilyang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

  • Difficulty controlling blood sugar in patients with type 2 diabetes
View approved original text

This medication is used to help control blood sugar levels in patients with type 2 diabetes in conjunction with diet and exercise. It can be taken alone, and when monotherapy is inadequate, it can be administered together with metformin. Additionally, it can be used in combination with sulfonylureas, metformin, thiazolidinediones, or insulin for patients who struggle to control their blood sugar with monotherapy. This medication aids in effective blood sugar management when added to various combination therapies. In this way, it improves blood sugar control flexibly in various situations.

How to take

Adult dose

This drug is administered once daily at a dose of 100 mg as monotherapy or in combination therapy, and the maximum daily dose is 100 mg. This drug may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see section 5. General Precautions, under Precautions for Use). Patients with renal impairment Since dosage adjustment is required according to renal function, evaluation of renal function is recommended before treatment with this drug and periodically thereafter. 1. No dosage adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. In patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. 4. In patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This drug may be administered regardless of the timing of dialysis.

Precautions

This medication may cause severe allergic reactions, so if skin rash, difficulty breathing, or swelling of the face or lips occurs after use, discontinue immediately and consult a doctor. This medication can cause serious inflammation of the pancreas called pancreatitis, so if abdominal pain, vomiting, or loss of appetite appears during use, inform healthcare professionals immediately. Patients with type 1 diabetes or diabetic ketoacidosis should not take this medication. Patients with reduced kidney function should have their dosage adjusted, so renal function tests should be performed before use, and follow the doctor's instructions. When taken with insulin or sulfonylureas, care should be taken to monitor blood sugar levels closely due to the risk of low blood sugar, and dosage adjustments of other medications may be necessary. During treatment with this medication, side effects such as headache, upper respiratory tract infections, nasopharyngitis, diarrhea, nausea, may occur, and if symptoms are severe, consult a doctor. Severe joint pain or skin blistering similar to bullous pemphigoid may occur, so if such symptoms occur, inform a doctor immediately. Pregnant or breastfeeding women should avoid taking this medication, and safety and efficacy in pediatric patients under 18 years of age have not been established. Older adults are encouraged to regularly monitor kidney function before and during treatment due to the potential decline in kidney function. In case of overdose, seek medical attention immediately for appropriate treatment; some medication can be removed via blood dialysis. There are few interactions with other medications, but consult a doctor or pharmacist when used in combination with certain medications.

Side effects

  • Severe allergic reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • exfoliative skin disease
  • acute pancreatitis
  • hypoglycemia
  • upper respiratory infection
  • nasopharyngitis
  • headache
Show 29 more
  • diarrhea
  • abdominal pain
  • nausea
  • constipation
  • vomiting
  • severe and debilitating arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • pneumonia
  • diabetes complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • increased serum triglycerides
  • gastritis
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in an airtight container to prevent air ingress and kept at room temperature between 1 degree and 30 degrees Celsius. Proper storage helps maintain the medication's efficacy.

Appearance and packaging

Appearance

Light orange, round, double-convex film-coated tablet

Package unit

30 tablets (10 tablets/PTP X 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.